Signatera | Applications | Natera

Publications and News

Publications and News

Publications and News

Publications and News

Our peer-reviewed research

  • Birkenkamp-Demtröder K, Christensen E, Sharma S, et al. Sequencing of plasma cfDNA from patients with locally advanced bladder cancer for surveillance and therapeutic efficacy monitoring. Poster presented at: American Association for Cancer Research Annual Meeting; April 17, 2018; Chicago, IL. Abstract 3653. - click here
  • Reinert T, Henriksen TV, Rasmussen MH, et al. Personalized circulating tumor DNA analysis to monitor colorectal cancer. Poster presented at: American Association for Cancer Research Annual Meeting; April 17, 2018; Chicago, IL. Abstract 1590. - click here
  • Sethi H, Salari R, Navarro S, et al. Analytical validation of the Signatera™ RUO assay, a highly sensitive patient-specific multiplex PCR NGS-based noninvasive cancer recurrence detection and therapy monitoring assay. Poster presented at: American Association for Cancer Research (AACR) Annual Meeting; April 17, 2018; Chicago, IL. Abstract 4542. - click here
  • Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451. - click here
  • Jamal-Hanjani M, Wilson GA, Horswell S, et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol. 2016;27(5):862-867.  - click here
  • Kirkizlar E, Zimmermann B, Constantin T, et al. Detection of clonal and subclonal copy-number variants in cell-free DNA from patients with breast cancer using a massively multiplexed PCR methodology. Transl Oncol. 2015;8:407-416. - click here
  • Babiarz JE, Zimmermann BG, Constantin T, et al. Detection of copy number variations in breast cancer samples using single-nucleotide polymorphism-targeted massively multiplexed PCR. Cancer Genet. 2014; 207(6):287.Babiarz J. et al. Detection of copy number variations in breast cancer samples using single-nucleotide polymorphism-targeted massively multiplexed PCR. Cancer Genetics 207, 287. (2014) - click here

Signatera (RUO) is for research use only and is not for use in diagnostic procedures.

Media

Contact us

Back to Top